Why GlaxoSmithKline plc, Telecom plus PLC and Kentz Corporation Limited Should Beat The FTSE 100 Today

GlaxoSmithKline plc (LON: GSK), Telecom plus PLC (LON: TEP) and Kentz Corporation Limited (LON: KENZ) move up on a dull day.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The FTSE 100 (FTSEINDICES: ^FTSE) ended yesterday with a 25-point loss, and it’s started today with a further dip of 16 points to 6,682 after ITV shares were downgraded following on from yesterday’s third-quarter update. But the index of top UK shares is only down 11 points on the week so far, and has gained 13% since the start of 2013 — could we be in for a late December surge to push us closer to that record 6,876 level from May?

There’s very little news of individual shares today, but here are three from the various indices that look set to beat the FTSE:

GlaxoSmithKline

Shares in GlaxoSmithKline (LSE: GSK) (NYSE:GSK.US) picked up 9.3p (0.6%) in early trading — not a big rise, but still welcome on a day when the FTSE is falling.

The news today is that the pharmaceuticals giant has completed the sale of part of its stake in Aspen Pharmacare Holdings, having agreed the sale of 28.2 million shares at a price of 250 rand per share. Following the sale, which will net about £425m, Glaxo will sill hold 56.5 million Aspen shares, or 12.4% of the company.

Glaxo shares have been erratic since the Spring, but they’re up around 22% over the past 12 months.

Telecom plus

We need to look outside the FTSE 100 for bigger rises today, and we see Telecom plus shares up a very nice 226p (15%) to 1,733p after the multi-utilities supplier released interim figures and announced an acquisition and share placing.

First-half revenue climbed 17% to £245.8m, with pre-tax profit up 10.1% to £13.7m. Adjusted earnings per share gained 11.5% to 15.5p, and the interim dividend was lifted 23% to 16p per share. These nice figures were made possible by a rise in customer numbers of 33,908, to 494,940.

Telecom Plus has also conditionally agreed to acquire Electricity Plus Supply and Gas Plus Supply from Npower, for a total price of £218m. The deal will be funded by a combination of a new share issue and £100m of borrowing, and will get Telecom plus a 20-year energy-supply deal.

Kentz Corporation

Our third riser for today is Kentz Corporation (LSE: KENZ), whose shares put on 16p (2.9%) to 558p after the company announced a $190m engineering contract with Qatar Petroleum for well-head control systems and corrosion protection for approximately 775 wells in the Dukhan Oilfield in Qatar.

Kentz shares have climbed strongly since the summer, and are now 47% ahead over the past 12 months.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> Alan does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

After a positive Q4 update, is the Vistry share price set to bounce back?

The Vistry share price has been falling sharply as a result of cost issues in its South Division. But the…

Read more »

Investing Articles

Is it game over for the Diageo share price?

The Diageo share price is showing as much spirit as an alcohol-free cocktail. Harvey Jones is wondering whether he should…

Read more »

Young Caucasian girl showing and pointing up with fingers number three against yellow background
Investing Articles

3 key reasons why AstraZeneca’s share price looks a steal to me right now

AstraZeneca’s share price has fallen a long way from its record-breaking level last year, which indicates that I may be…

Read more »

Investing Articles

Here’s how investors could aim for a £6,531 annual passive income from £11,000 of Aviva shares

As a stock’s yield rises when its price falls, I'm not bothered by Aviva shares’ apparent inability to break the…

Read more »

Investing Articles

3 million reasons why earning a second income is more important than ever

With AI posing a threat to UK jobs, our writer considers ways to earn a second income by investing in…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

With an 8% yield, is the second-largest FTSE 250 stock worth considering?

Our writer considers the value of the second-largest stock on the FTSE 250 with a £4bn market cap and a…

Read more »

Close-up of British bank notes
Investing Articles

10%+ dividend yields! 3 top dividend shares to consider in 2025!

Investing in these high-yield UK dividend shares could deliver a huge passive income for years to come. Royston Wild explains…

Read more »

Bearded man writing on notepad in front of computer
Investing Articles

Greggs’ share price tanked last week. So I bought more!

Could Greggs be one of the FTSE 250's best bargains following its share price slump? Royston Wild thinks so, as…

Read more »